Osteoprotegerin-deficient male mice as a model for severe alveolar bone loss: Comparison with RANKL-overexpressing transgenic male mice

Endocrinology

Volumn 154, Issue 2, 2013, Pages 773-782

  Koide, Masanori ^a   Kobayashi, Yasuhiro ^a   Ninomiya, Tadashi ^a   Nakamura, Midori ^a   Yasuda, Hisataka ^b   Arai, Yoshinori ^c   Okahashi, Nobuo ^d   Yoshinari, Nobuo ^a   Takahashi, Naoyuki ^a   Udagawa, Nobuyuki ^a  

^a MATSUMOTO DENTAL UNIVERSITY   (Japan)

^b Oriental Yeast Co Ltd   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RISEDRONIC ACID;

ALVEOLAR BONE LOSS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICAL BONE; DISEASE SEVERITY; GENE OVEREXPRESSION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

ALVEOLAR BONE LOSS; ANIMALS; MALE; MANDIBULAR DISEASES; MICE; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOPROTEGERIN; PERIODONTITIS; RANK LIGAND;

EID: 84872724287     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1928     Document Type: Article

References (46)

1. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010;8:481-490.
2. Nibali L, Donos N, Henderson B. Periodontal infectogenomics. J Med Microbiol. 2009;58:1269-1274.
3. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol. 2008;79:1569-1576.
4. Koide M, Kinugawa S, Takahashi N, Udagawa N. Osteoclastic bone resorption induced by innate immune responses. Periodontol 2000. 2010;54:235-246.
5. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637-650.
6. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345-357. (Pubitemid 30649812)
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342. (Pubitemid 40852708)
8. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292-304. (Pubitemid 46480961)
9. Roodman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci. 2006;1068:100-109. (Pubitemid 43824141)
10. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990;345:442-444. (Pubitemid 120014957)
11. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597-3602.
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176. (Pubitemid 28180851)
13. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319. (Pubitemid 27199902)
14. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998;139:1329-1337. (Pubitemid 28510154)
15. Onyia JE, Miles RR, Yang X, et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res. 2000;15:863-871. (Pubitemid 30233409)
16. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231-1234.
17. Lu HK, Chen YL, Chang HC, Li CL, Kuo MY. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res. 2006;41:354-360. (Pubitemid 44392308)
18. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res. 2004;83:166-169. (Pubitemid 41713803)
19. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998;247:610-615. (Pubitemid 28418439)
20. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268. (Pubitemid 28213402)
21. Mizuno A, Kanno T, Hoshi M, et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab. 2002;20:337-344. (Pubitemid 40645655)
22. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363:2027-2035.
23. Kim HK, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res. 2006;21:1946-1954. (Pubitemid 44851571)
24. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059-1066. (Pubitemid 41110556)
25. Cetinkaya BO, Keles GC, Ayas B, Gurgor P. Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. J Periodontol. 2008;79:1950-1961.
26. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21:349-353. (Pubitemid 43962658)
27. Rocha ML, Malacara JM, Sanchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol. 2004;75:1579-1585. (Pubitemid 40260006)
28. Teng YT, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest. 2000;106:R59-R67.
29. Furuya Y, Mori K, Ninomiya T, et al. Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-κB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. J Biol Chem. 2011;286:37023-37031.
30. Kinugawa S, Koide M, Kobayashi Y, et al. Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells. J Immunol. 2012;188:1772-1781.
31. Ninomiya T, Hosoya A, Nakamura H, Sano K, Nishisaka T, Ozawa H. Increase of bone volume by a nanosecond pulsed laser irradiation is caused by a decreased osteoclast number and an activated osteoblasts. Bone. 2007;40:140-148. (Pubitemid 44839344)
32. Tanaka M, Toyooka E, Kohno S, Ozawa H, Ejiri S. Long-term changes in trabecular structure of aged rat alveolar bone after ovariectomy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:495-502. (Pubitemid 36877327)
33. Kimura M, Miyazawa K, Tabuchi M, Maeda H, Kameyama Y, Goto S. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. Calcif Tissue Int. 2008;82:137-147.
34. Evans RT, Klausen B, Sojar HT, et al. Immunization with Porphyromonas (Bacteroides) gingivalis fimbriae protects against periodontal destruction. Infect Immun. 1992;60:2926-2935.
35. Sheng ZF, Xu K, Ma YL, et al. Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. Osteoporos Int. 2009;20:151-159.
36. Nakamura M, Udagawa N, Matsuura S, et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology. 2003;144:5441-5449. (Pubitemid 37476073)
37. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751-764. (Pubitemid 40585297)
38. Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30:3071-3085.
39. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res. 2009;24:1651-1661.
40. Suda K, Udagawa N, Sato N, et al. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide- induced osteoclast formation. J Immunol. 2004;172:2504-2510. (Pubitemid 38182401)
41. Yasuhara R, Miyamoto Y, Takami M, et al. Lysine-specific gingipain promotes lipopolysaccharide- and active-vitamin D3-induced osteoclast differentiation by degrading osteoprotegerin. Biochem J. 2009;419:159-166.
42. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682. (Pubitemid 26091143)
43. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363-14367. (Pubitemid 28319153)
44. Yen ML, Hsu PN, Liao HJ, Lee BH, Tsai HF. TRAF-6 dependent signaling pathway is essential for TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation. PLoS One. 2012;7:e38048.
45. Lucas H, Bartold PM, Dharmapatni AA, Holding CA, Haynes DR. Inhibition of apoptosis in periodontitis. J Dent Res. 2010;89:29-33.
46. Torres J, Tamimi F, Garcia I, et al. Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:387-392.